What is the clinical evidence from this study?

Study design: Cohort. Population: Biopsy-proven viral myocarditis (n=222). Intervention: Late gadolinium enhancement (LGE) vs. Absence of LGE. Primary outcome: All-cause mortality (HR 8.4).

What does this research mean for the field?

In patients with biopsy-proven viral myocarditis, the presence of late gadolinium enhancement on cardiovascular magnetic resonance is the strongest independent predictor of long-term all-cause and cardiac mortality. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate long-term clinical outcomes, survival rates, and cardiac function trajectories in patients diagnosed with biopsy-proven viral myocarditis.

September 16, 2026Journal of the American College of Cardiology

Long-Term Follow-Up of Biopsy-Proven Viral Myocarditis

View Full Paper

Ask AI

Bookmark

Key result

LGE in viral myocarditis is linked to ~8-fold higher all-cause mortality.

HR 8.4
n=222

Population

222 consecutive patients with biopsy-proven viral myocarditis who underwent cardiovascular magnetic resonance

Design

Cohort

Follow-up

median 4.7 years

Authors

SGStefan GrünRems-Murr-Klinikum JSJulia SchummHelios Dr. Horst Schmidt Kliniken Wiesbaden SGSimon GreulichCardiac Imaging

Discussion

Member takes

Implication

The presence of late gadolinium enhancement on CMR is a powerful independent predictor of long-term mortality in patients with biopsy-proven viral myocarditis.

Key Points

To evaluate long-term clinical outcomes, survival rates, and cardiac function trajectories in patients diagnosed with biopsy-proven viral myocarditis.
Tracked clinical status longitudinally in patients with viral myocarditis verified through endomyocardial biopsy.
Monitored cardiac functional parameters, left ventricular ejection fraction, and adverse cardiovascular events over long-term follow-up.
Long-term clinical trajectories vary widely among patients following biopsy-confirmed viral myocardial inflammation.
A clinically significant subset of patients develops persistent or progressive left ventricular dysfunction and chronic heart failure over extended follow-up.

Study Design

Type

Cohort (n=222)

Structured PICO

Population

222 consecutive patients with biopsy-proven viral myocarditis who underwent cardiovascular magnetic resonance, followed for a median of 4.7 years.

Outcome

All-cause mortality and cardiac mortalityhard clinical

Main Result

Hazard Ratio: 8.4

The presence of late gadolinium enhancement on CMR is a powerful independent predictor of long-term mortality in patients with biopsy-proven viral myocarditis.

Cite This Study

Grün et al. (2012) conducted a cohort in Biopsy-proven viral myocarditis (n=222). Late gadolinium enhancement (LGE) vs. Absence of LGE was evaluated on All-cause mortality (HR 8.4). The presence of late gadolinium enhancement in patients with biopsy-proven viral myocarditis strongly predicted all-cause mortality (HR 8.4) and cardiac mortality (HR 12.8) over 4.7 years.

synapsesocial.com/papers/6aaa2d998a8dafe49ec2f40f https://doi.org/10.1016/j.jacc.2012.01.007

Topics

Myocarditis Cardiac MRI

View Full Paper

Ask AI

Bookmark

Implication

The presence of late gadolinium enhancement on CMR is a powerful independent predictor of long-term mortality in patients with biopsy-proven viral myocarditis.

Long-Term Follow-Up of Biopsy-Proven Viral Myocarditis

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Topics

Long-Term Follow-Up of Biopsy-Proven Viral Myocarditis

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Also Consider

Topics

Also Consider